Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mindful Eating, Orthorexic Tendency, and Mediterranean Diet Adherence Identify Weight-Related Eating Profiles in Young Adults.

Nutrients·2026
Same author

TTP-like syndrome revealing advanced HIV infection: a case of secondary multifactorial thrombotic microangiopathy.

MedScience·2026
Same author

The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.

Molecular oncology·2026
Same author

Overweight and obesity increase breast cancer risk in postmenopausal women: a meta-analysis of 38 observational studies.

GeroScience·2026
Same author

Botanical and Upcycled Bioactives for Advanced Topical Formulations: Mechanistic Pathways, Cutaneous Delivery, and Sustainability-by-Design.

Pharmaceutics·2026
Same author

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.

Pharmaceuticals (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jun 27, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

JQ1 Downregulates IL-20RA Expression in Triple Negative Breast Cancer Cells In Vitro and In Vivo.

Valentina Maggisano1, Salvatore Panza2, Antonella Verrienti3

  • 1Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.

International Journal of Molecular Sciences
|June 26, 2026
PubMed
Summary

Bromodomain and Extra-Terminal domain (BET) inhibitor JQ1 downregulates IL-20 receptor subunit alpha (IL-20RA) in triple-negative breast cancer (TNBC). This reduces tumor progression and resistance by inhibiting the IL-20RA/STAT3 pathway and PD-L1 expression.

Keywords:
BET-inhibitorIL-20RAJQ1TMETNBC

Related Experiment Videos

Last Updated: Jun 27, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) progression and treatment resistance involve complex tumor microenvironment (TME) interactions.
  • Overexpression of IL-20 receptor subunit alpha (IL-20RA) signaling is implicated in breast cancer (BC) invasion and metastasis.
  • Bromodomain and Extra-Terminal domain (BET) proteins epigenetically regulate oncogenic pathways and cytokine expression in TNBC.

Purpose of the Study:

  • To investigate the regulatory effects of the BET inhibitor JQ1 on the IL-20RA pathway in TNBC.
  • To determine if JQ1 impacts IL-20RA expression and associated oncogenic signaling in TNBC cells.
  • To explore the therapeutic potential of JQ1 in TNBC models with high IL-20RA expression.

Main Methods:

  • Quantification of IL-20RA expression in various BC cell lines.
  • Treatment of TNBC cell lines (MDA-MB-231, MDA-MB-468) with JQ1 and assessment of IL-20RA, JAK/STAT pathway, and PD-L1 expression at gene and protein levels.
  • In vivo studies using TNBC xenograft models to evaluate the effects of JQ1 on IL-20RA, PD-L1, and JAK/STAT3 phosphorylation.

Main Results:

  • IL-20RA was expressed in BC cell lines, notably higher in MDA-MB-231 and MDA-MB-468 cells.
  • JQ1 treatment significantly downregulated IL-20RA at both gene and protein levels in TNBC cells.
  • JQ1 reduced JAK/STAT signaling pathway activity and programmed death-ligand 1 (PD-L1) expression, confirmed in vivo.
  • In vivo experiments showed decreased IL-20RA and PD-L1 expression and reduced JAK/STAT3 phosphorylation upon JQ1 treatment.

Conclusions:

  • A novel interplay between BET inhibition and the IL-20RA/STAT3 axis in TNBC was uncovered.
  • JQ1 effectively downregulates IL-20RA and associated oncogenic pathways in TNBC.
  • JQ1 represents a potential therapeutic strategy for TNBC, particularly in cases with elevated IL-20RA expression.